The neuroendocrine cancer community came together in Atlanta for a powerful day of education, connection, and hope. Read the full recap and the recordings of the speaker presentations: ncf.net/post/ncf-s-patient-e… NCF’s Patient Education Event welcomed approximately 110 patients, caregivers, clinicians, scientists, advocates, and industry partners for expert-led sessions on surgery, liver-directed therapy, systemic treatments, imaging, PRRT, clinical trials, and emerging research. Attendees heard from leading regional experts from Emory University, UAB, and Vanderbilt, connected with others who understand the NET journey, and left with practical knowledge, new relationships, and renewed hope. Thank you to our speakers, sponsors, partners, and everyone who joined us in Atlanta. Together, we are advancing education, awareness, and support for the neuroendocrine cancer community. #NeuroendocrineCancer #NETCancer #patienteducation #cancersupport #clinicaltrials #PRRT #cancercommunity #ncfcancer

Today’s update from Johnnie! What an amazing achievement. Thankyou from everyone at #TeamMeeks to each and every one of you who show us support, without you - we wouldn’t be able to do all the good that we do for others, while raising #NETCancer awareness 🦓🤍🖤

📢 Highlights from the ENETS 2026 Conference Discover the latest clinical practice changing insights from the ENETS 2026 conference in Krakow, Poland. Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch to find out. 📺 See more: cor2ed.com/net-connect/progr… This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #OncTwitter #NETs #NeuroendocrineTumors #NeuroendocrineCancer #NETCancer

What an incredible day at the Neuroendocrine Cancer Patient Conference in Atlanta, with over 100 incredibly engaged guests! We are so grateful to @UGrewalMD, our speakers, patients, caregivers, clinicians, advocates and sponsors for coming together to learn, connect, and support one another. Seeing such a strong turnout reminds us of the power and resilience of this incredible community. A special thank you to our outstanding speakers from Emory, Vanderbilt, and UAB, as well as our generous sponsors, for helping make this event possible. 💚 #neuroendocrinecancer #netcancer #netawareness

🩵The nurses that are specialized in neuroendocrine cancer are lifelines for our community. We are grateful for the grace and unwavering work they do daily. #HealingNET #NeuroendocrineCancer #NursesMonth #NETcancer

The reality of living with #NETcancer .. This was Johnnie’s update yesterday after his 119th Lanreotide treatment! Ouch!! But definitely worth it pal! 🦓🤍🖤

If you can donate, share, or repost, it would truly mean everything to me ❤️ [gofundme.com/f/help-g-p-hars…] #Cancer #NETCancer #GoFundMe #MedicalFundraiser #CancerSupport

No rest when you’re living with #NETcancer. Johnnie’s update today from the prosthetics clinic! Looking good Mr Meeks! Keep up the good work! 🦓🤍🖤

Sorry it’s a bit late tonight but just want to wish all our followers in England a very Happy St George’s Day! 🏴󠁧󠁢󠁥󠁮󠁧󠁿 Hope you’ve all had a pleasant day! Our Ellie has 4 days to go til the big jump! Raising awareness of #NETcancer 🦓🤍🖤

Tonight’s update from Johnnie. Really great to see him doing so well. He’s put hard graft in and hopefully soon he’ll be up and about again 🙏 Looking fabulous Mr Meeks, well done! #prosthetics #amputee #NETcancer 🦓🤍🖤

Ok, now we’re getting somewhere. I can relate. Jan 2015 I underwent Chemo for NetCancer myself. It’s scary. And I was VERY lucky, I was stage 1. I can’t even imagine how scary this has been for you.

Update from #ENETS2026 📺 Get key takeaways from the congress, including: 🔎 Results of the COMPETE trial subgroup analysis comparing PRRT and everolimus 🔎 What the latest data from the DAREONᵀᴹ-7 trial reveal about obrixtamig, a DLL3 bi-specific T cell engager 🔎 The role of surgical resection in stage 1–3 NECs 🔎Strategies for re-challenging PRRT in NET patients 🔎 The interesting combination treatment of cabozantinib and temozolomide for NETs From Prof. Louis de Mestier, Prof. Timon Vandamme (@TimonV), & Dr Alice Durand See more! >> cor2ed.com/net-connect/progr… This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #OncTwitter #NETs #NeuroendocrineTumors #NeuroendocrineCancer #NETCancer

📺 Découvrez les dernières avancées susceptibles de modifier la pratique clinique, présentées lors du congrès #ENETS2026 à Cracovie, en Pologne. Le Pr Louis de Mestier, le Pr Timon Vandamme et le Dr Alice Durand partagent leurs analyses des nouvelles données concernant la RIV ans la séquence thérapeutique et le retraitement (re‑challenge) des TNE, l’obrixtamig en traitement de première ligne des CNE avancés, ainsi que le rôle de la chirurgie dans les maladies de stade 1 à 3. Ils discutent également l’association thérapeutique intéressante. Quel impact les nouvelles données vont avoir sur la pratique clinique ? Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen. Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale #MedEd #NeuroendocrineTumors #NeuroendocrineCancer #NETs #NETCancer

📺 Highlights from #ENETS2026 Discover the latest clinical practice changing insights from the conference in Krakow, Poland. Experts Prof. Louis de Mestier, Prof. @TimonV and Dr Alice Durand share insights into new data on PRRT in treatment sequencing and re-challenge in NETs, obrixtamig as 1st line therapy in advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss interesting combination treatment. How will new data impact clinical practice? Watch the video below to find out. This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community. #MedEd #NeuroendocrineTumors #NeuroendocrineCancer #NETs #NETCancer

➡️ Register at ncf.net/events/mar2026 Join us for a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. #NeuroendocrineCancer #NETCancer #TargetedTherapy #cancereducation #cancerresearch #ncfcancer #NeuroendocrineTumor

Today, we honor a 60-year legacy — and look ahead with purpose. After nearly 60 years of service, the @CarcinoidNETs (CCF), founded by Dr. Richard R.P. Warner, has announced it is closing operations. We are honored that the Neuroendocrine Cancer Foundation (NCF) was chosen as CCF’s successor organization. Over the past two years, NCF has worked closely alongside CCF to ensure continuity of support. 💙What This Means for Our Community: 🧡A new, unified Neuroendocrine Cancer Provider Directory — developed in partnership with the Neuroendocrine Tumor Research Foundation (NETRF) — will launch later this year to help patients connect with experienced providers 🧡The Patient Support Line will continue 🧡Luncheon with the Experts (LWTE) webinars will continue 🧡Stories of Hope will continue to amplify patient and caregiver voices We are deeply grateful to CCF and to Keith Warner and @GraceGoldstein for their decades of leadership, service, and unwavering dedication to the NET community. Their confidence in NCF is something we do not take lightly. Our commitment remains clear: no one facing neuroendocrine cancer should feel alone. We will continue building on this legacy with trusted education, compassionate support, and meaningful connection. — The NCF Team #NeuroendocrineCancer #NETCancer #ContinuingTheLegacy #PatientSupport #cancercommunity #NeuroendocrineTumor #netawareness

It was a pleasure having @AGangiMD on @MoffittNews campus. So grateful for the time and expertise she shared with us all. Maybe next time she can stay for longer….Not enough time!! #AHPBA #AcademicTwitter #NETCancer #NANETS #Surgonc

📌 Call to Action Care partners and caregivers play a vital role in supporting people living with neuroendocrine carcinoma—and your voice matters. If you are caring for someone with NEC, you’re invited to take part in a confidential online survey to help researchers better understand the challenges you face and how support can be improved. ✅ Short online survey ✅ Confidential ✅ Honorarium provided for eligible participants Your experience can help shape better care for the NEC community. ➡️ Learn more and sign up here: s-hab.medefield.com/wix/p294… #NeuroendocrineCancer #CaregiverSupport #CarePartner #PatientSupport #ncfcancer #NETCancer #NeuroendocrineTumor

Keep raising awareness! #netcancer #LetstalkaboutNets

Missed our December webinar with @AmanChauhanMD? You can now watch the full December webinar at your convenience. 💻Watch here: ncf.net/events/dec2025 After viewing, please take a moment to complete our short survey—your feedback helps shape future programs and better support our community. ➡️Take the survey: forms.gle/SBWAftnpUWbB1MDJ9 @CarcinoidNETs @NANETS1 #NeuroendocrineCancer #NETCommunity #CancerEducation #PatientSupport #ncfcancer #NeuroendocrineTumor #NETCancer